Carregant...
R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. Th...
Guardat en:
| Publicat a: | Chin Med J (Engl) |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams & Wilkins
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7846449/ https://ncbi.nlm.nih.gov/pubmed/33323828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000001294 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|